Consolidation Therapy for Locally Advanced NSCLC
Consolidation Therapy for Locally Advanced NSCLC
Case: A 59-year-old Woman With Locally Advanced NSCLC
- A 59-year-old woman presents after referral from primary care for persistent cough and bloody sputum. She denies shortness of breath, says cough began last fall and she attributes it and the sputum to allergies.
- History:
- 10-year smoking history, ages 15 to 25
- Postmenopausal, BMI = 26 kg/m2
- Basal cell carcinoma on chest and face, had 3 lesions removed 2 years ago
- Evaluation and follow up testing reveal stage IIIB NSCLC:
- Radiograph shows 2 lesions in left lung (3.1 cm and 5.5 cm)
- Fiber optic bronchoscopy identifies NSCLC
- Endobronchial ultrasound reveals ipsilateral mediastinal lymph node involvement
- WHO performance status 1
- Histology: nonsquamous
- Biomarkers
- EGFRnegative,BRAFnegative,ALK/ROS1negative
- PD-L1 status: >25%
- Laboratory findings:
- WBC, renal function, hepatic function within normal ranges
- After multidisciplinary evaluation, the patient was determined not to be a surgical candidate
- She completed a weekly carboplatin/paclitaxel doublet therapy with concomitant radiotherapy (60 Gy)
- Achieved partial response without progression 3 weeks later
- Began treatment with durvalumab
Related Videos
Related Content
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Article
Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
